CN113349381A

CN113349381A - Food composition capable of relieving depression and preparation method thereof

Info

Publication number: CN113349381A
Application number: CN202110614469.4A
Authority: CN
Inventors: 周宁
Original assignee: Acorn Fitness Industrial Investment Co ltd
Current assignee: Acorn Fitness Industrial Investment Co ltd
Priority date: 2021-06-02
Filing date: 2021-06-02
Publication date: 2021-09-07

Abstract

The invention discloses a food composition for relieving depression and a preparation method thereof, wherein the food composition comprises the following components in parts by weight: 0.1-15 parts of casein hydrolysate peptide, 0.01-1 part of melissa officinalis extract, 0.01-1 part of yellow chrysanthemum extract, 0.01-1 part of valerian root extract, 0.01-1 part of saffron extract, 0.1-5 parts of blueberry extract, 0.1-5 parts of tremella extract and 0.1-5 parts of ginseng extract; adding adjuvants into the food composition, and making into tablet, oral liquid, powder and jelly; the traditional Chinese medicine composition combines the traditional medicine-food homologous traditional Chinese medicine and modern new food technical raw materials, has the characteristics of multiple factors and multiple targets, is more targeted to the treatment or alleviation of the depression, is safer to take, and has no obvious toxic or side effect.

Description

Food composition capable of relieving depression and preparation method thereof

Technical Field

The invention belongs to the technical field of foods, and particularly relates to a food composition capable of relieving depression and a preparation method thereof.

Background

Depression is a common affective disorder, a disease that persists in mood or in mood decline, lack of interest, bradythought with physical symptoms such as anorexia, sexual dysfunction, sleep disturbance, and the like. With the rapid development of society, the pressure of people on work and life is gradually increased, depression is developed into a general mental disorder disease which seriously threatens human health, and even serious depression can cause suicide of patients. Recent survey results published by the World Health Organization (WHO) show that the global depression incidence is about 3.1%, about 2.3 hundred million depression patients exist in the world at present, and depression currently becomes the fourth disease in the world.

At present, the common western medicines for treating depression comprise fluoxetine, amitriptyline, venlafaxine and the like, but mainly have the defects of single target, low treatment rate, large side effect, high price and the like. Therefore, people urgently need a functional food which has obvious effect, is safe and reliable, is convenient to take and can achieve the aim of relieving depression in a healthy and easy way.

Disclosure of Invention

Aiming at the problems of single target, low treatment rate, large side effect and high price of the existing western medicines, the invention provides a food composition for relieving depression.

The invention adopts the following technical scheme: a food composition for relieving depression comprises the following components in parts by weight: 0.1-15 parts of casein hydrolysate peptide, 0.01-1 part of melissa officinalis extract, 0.01-1 part of yellow chrysanthemum extract, 0.01-1 part of valerian root extract, 0.01-1 part of saffron extract, 0.1-5 parts of blueberry extract, 0.1-5 parts of tremella extract and 0.1-5 parts of ginseng extract. The yellow chrysanthemum extract is preferably German spring yellow chrysanthemum extract, and the edible essence is preferably glucosyl stevioside.

Has the advantages that:

the depsipeptide is a physiologically active substance, is a component obtained by hydrolyzing casein extracted from skim milk with plant digestive enzymes, and has obvious effects on relieving pressure and resisting depression.

Melissa officinalis, namely Ma mint, American mint, lemon balm, melissa officinalis and melissa officinalis, is a perennial herb of Melissa of Labiatae; melissa is a traditional national herb widely used with mild sedatives, spasmolytics and antiseptics; the Melissa officinalis extract can be used as mild sedative or sedative for treating anxiety, and has effect in improving mental mood; the experiment proves that the rosmarinic acid can inhibit GABA transaminase to inhibit GABA degradation, improve GABA concentration in brain, and has the effects of tranquilizing and relieving, and resisting anxiety and depression, and in addition, the melissa officinalis has two other main components: caffeic acid, citral also has anxiolytic and antidepressant effects.

The yellow chrysanthemum is a plant of the Compositae family, is rich in active ingredients such as chamazulene, alpha-bisabolol, sesquiterpene, apigenin, quercetin, luteolin and the like, acts on neurotransmitter, not only improves the sleep quality, but also can effectively relieve depression.

The rhizoma et radix Valerianae is dried root and rhizome of Valeriana officinalis of Valerianaceae. The valerian root is cold in nature, pungent and bitter in taste, enters heart and liver channels, has the effects of tranquilizing and allaying excitement, relieving spasm and relieving pain, is rich in Valeriana officinalis L.var.officinalis L.var.var.officinalis L.var.officinalis L.var.var.officinalis L.var.var.Valeriana L.var.var.var.var.var.var.var.officinalis L.var.var.var.var.var.var.var.var.officinalis L.var.var.var.var.var.var.officinalis L.var.var.var.officinalis L.var.var.officinalis L.officinalis L.var.officinalis L.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.var.is rich in volatile oil components and volatile oil components, and can obviously resist depression activity.

Saffron, also known as crocus sativus and saffron, is a perennial flower of crocus genus of iridaceae family, and is also a common spice. The saffron extract has mood-relieving and anxiolytic, depressive properties without side effects.

The blueberry belongs to Vaccinium of Ericaceae, and contains abundant nutrients such as anthocyanin, polysaccharide, protein, fat, VA, VE, SOD, etc., and abundant microelements such as calcium, phosphorus, magnesium, ferrum, copper, germanium, etc. The blueberry extract has obvious depression resisting effect.

Tremella is the fruiting body of fungi of Basidiomycota, Tremellaceae, Tremellales, Tremellaceae, Tremella, also called Tremella, etc., and is named as "crown of fungus", and is rich in Tremella polysaccharide as active ingredient. The tremella extract has obvious antidepressant activity.

Ginseng is the rhizome of plant of Araliaceae, and has sweet, slightly bitter and warm taste. It enters spleen, lung, heart and kidney meridians. The ginseng has the main effects of greatly reinforcing primordial qi, tonifying spleen and lung, promoting the production of body fluid and nourishing blood, soothing the nerves and improving intelligence, and the main active component of the ginseng is saponins which can resist depression by regulating cell factors and changing the number of astrocytes and increase the content of monoamine neurotransmitters in brain.

The ginseng and the tremella can improve the content of neurotransmitter in the brain, and the effective components in the yellow chrysanthemum act on the neurotransmitter, so that the ginseng, the tremella and the yellow chrysanthemum have a synergistic effect and can enhance the anti-depression capacity; and some active ingredients in the yellow chrysanthemum can act on GABA receptors to improve the activity of the GABA receptors and facilitate the combination of the GABA receptors, and part of active ingredients in the melissa can inhibit GABA transaminase to inhibit the degradation of GABA, improve the GABA concentration in brain, increase the contact chance with the GABA receptors, and finally achieve the purpose of relieving depression.

In conclusion, the traditional Chinese medicine with homology of medicine and food is combined with modern new food technical raw materials, so that the traditional Chinese medicine has the characteristics of multiple factors and multiple targets, is more targeted for treating or relieving depression, is safer to take, and has no obvious toxic or side effect.

Further defined, the food composition for relieving depression comprises the following components in parts by weight: 8 parts of casein hydrolysate peptide, 0.34 part of melissa officinalis extract, 0.45 part of yellow chrysanthemum extract, 0.57 part of valerian root extract, 0.61 part of saffron extract, 3.9 parts of blueberry extract, 2.8 parts of tremella extract and 1.5 parts of ginseng extract.

Further limited, the food composition also comprises the following components in parts by mass: 65-95 parts of purified water, 3-10 parts of erythritol, 0.01-0.3 part of citric acid monohydrate, 0.01-0.3 part of sodium citrate, 0.01-0.3 part of DL-malic acid, 0.01-0.05 part of potassium sorbate, 0.001-0.005 part of sucralose and 0.01-0.2 part of edible spice.

Further limited, the food composition also comprises the following components in parts by mass: 10-35 parts of xylitol, 25-50 parts of isomalt, 0.5-1.5 parts of magnesium stearate, 0.2-0.8 part of silicon dioxide and 0.01-0.2 part of edible flavor.

Further limited, the food composition also comprises the following components in parts by mass: 65-95 parts of purified water, 0.5-2 parts of jelly powder, 3-10 parts of erythritol, 0.01-0.3 part of citric acid monohydrate, 0.01-0.3 part of sodium citrate, 0.01-0.05 part of potassium sorbate, 0.001-0.005 part of sucralose and 0.01-0.2 part of edible spice.

Further limited, the food composition also comprises the following components in parts by mass: 10-35 parts of xylitol, 15-60 parts of polydextrose, 0.2-0.8 part of silicon dioxide, 0.001-0.01 part of sucralose, 0.01-0.5 part of citric acid monohydrate, 0.01-0.5 part of sodium citrate and 0.01-0.2 part of edible spice.

The invention also discloses a preparation method of the food composition for relieving depression, which comprises the following steps:

premixing casein hydrolysate peptide, Melissa officinalis extract, yellow chrysanthemum extract, valerian root extract, saffron extract, blueberry extract, tremella extract, potassium sorbate and ginseng extract at 55-65 ℃, adding purified water, and stirring for dissolving to obtain a mixed solution 1;

sequentially adding erythritol, citric acid monohydrate, malic acid and sodium citrate into the mixed solution 1 to obtain a mixed solution 2;

homogenizing the mixed solution 2 at 55-65 deg.C, adding purified water and edible flavor, and making into desired volume.

premixing casein hydrolysate peptide, Melissa officinalis extract, yellow chrysanthemum extract, valerian root extract, saffron extract, blueberry extract, tremella extract, potassium sorbate and ginseng extract to obtain a mixture 1;

mixing mixture 1, xylitol, isomalt, magnesium stearate, silicon dioxide and flavoring to obtain mixture 2;

and removing impurities from the mixture 2 and tabletting.

mixing casein hydrolysate peptide, Melissa officinalis extract, yellow chrysanthemum extract, valerian root extract, saffron extract, blueberry extract, tremella extract, ginseng extract, citric acid monohydrate, sodium citrate, sucralose and edible spice to obtain a mixture 3;

premixing the jelly powder, erythritol and potassium sorbate, adding purified water, and heating to dissolve to obtain a mixed solution 3;

and mixing the mixture 3 and the mixed solution 3, and fixing the volume.

The invention also discloses a preparation method of the food composition for relieving depression, which comprises the following steps: sieving casein hydrolysate peptide, Melissa officinalis extract, yellow chrysanthemum extract, rhizoma et radix Valerianae extract, stigma croci Sativi extract, fructus Myrtilli extract, Tremella extract, potassium sorbate and Ginseng radix extract respectively, and premixing to obtain mixture 4;

screening xylitol, polydextrose, silicon dioxide, sucralose, citric acid monohydrate, sodium citrate and edible spice respectively, and premixing to obtain a mixture 5;

mixing the mixture 4 and the mixture 5.

Detailed Description

Example 1

The preparation of the oral liquid for relieving depression in a 10 ten thousand grade clean area comprises the following steps:

s1: inspecting and screening qualified raw materials, and weighing the following raw materials by mass: 100kg of casein hydrolysate peptide, 10kg of melissa officinalis extract, 10kg of German chamomile extract, 10kg of valerian root extract, 10kg of saffron extract, 100kg of blueberry extract, 100kg of tremella extract, 100kg of ginseng extract, 10kg of potassium sorbate, 65000kg of purified water, 3000kg of erythritol, 10kg of citric acid monohydrate, 10kg of sodium citrate, 10kg of DL-malic acid, 1kg of sucralose and 10kg of glucosyl stevioside;

s2: filling heating medium water into an interlayer in a container which has an interlayer structure and can be heated, maintaining the temperature of the water at 55-65 ℃, premixing casein hydrolysate peptide, lemon balm extract, German chamomile extract, valerian root extract, saffron extract, blueberry extract, tremella extract, ginseng extract and potassium sorbate, adding part of purified water, and stirring to obtain a mixed solution 10;

s3: sequentially adding erythritol, citric acid, malic acid and sodium citrate into the mixed solution 10, and mixing to obtain a mixed solution 11;

s4: homogenizing the mixed solution 11, and adding the rest purified water to constant volume to obtain oral liquid;

s5: encapsulating the oral liquid (40 + -5 deg.C, 30 ml/bottle), sterilizing (105 deg.C, 30min), cooling to below 60 deg.C, inspecting under lamp, packaging, inspecting, and warehousing.

Example 2

s1: inspecting and screening qualified raw materials, and weighing the following raw materials by mass: 8000kg of casein hydrolysate peptide, 300kg of melissa officinalis extract, 450kg of German chamomile extract, 800kg of valerian root extract, 300kg of saffron extract, 3200kg of blueberry extract, 4001kg of tremella extract, 2100kg of ginseng extract, 40kg of potassium sorbate, 81000kg of purified water, 7240kg of erythritol, 150kg of citric acid monohydrate, 157kg of sodium citrate, 230kg of DL-malic acid, 3kg of sucralose and 140kg of glucosyl stevioside;

s2: filling heating medium water into an interlayer in a container which has an interlayer structure and can be heated, maintaining the temperature of the water at 55-65 ℃, premixing casein hydrolysate peptide, lemon balm extract, German chamomile extract, valerian root extract, saffron extract, blueberry extract, tremella extract, ginseng extract and potassium sorbate, adding part of purified water, and stirring to obtain a mixed solution 12;

s3: sequentially adding erythritol, citric acid, malic acid and sodium citrate into the mixed solution 12, and mixing to obtain a mixed solution 13;

s4: homogenizing the mixed solution 13, and adding the rest purified water to the mixed solution to a constant volume to obtain an oral liquid;

Example 3

s1: inspecting and screening qualified raw materials, and weighing the following raw materials by mass: 15000kg of casein hydrolysate peptide, 1000kg of melissa officinalis extract, 1000kg of German chamomile extract, 1000kg of valerian root extract, 1000kg of saffron extract, 5000kg of blueberry extract, 5000kg of tremella extract, 5000kg of ginseng extract, 50kg of potassium sorbate, 95000kg of purified water, 10000kg of erythritol, 300kg of citric acid monohydrate, 300kg of sodium citrate, 300kg of DL-malic acid, 5kg of sucralose and 200kg of glucosyl stevioside;

s2: filling heating medium water into an interlayer in a container which has an interlayer structure and can be heated, maintaining the temperature of the water at 55-65 ℃, premixing casein hydrolysate peptide, lemon balm extract, German chamomile extract, valerian root extract, saffron extract, blueberry extract, tremella extract, ginseng extract and potassium sorbate, adding part of purified water, and stirring to obtain a mixed solution 14;

s3: sequentially adding erythritol, citric acid, malic acid and sodium citrate into the mixed solution 14, and mixing to obtain a mixed solution 15;

s4: homogenizing the mixed solution 15, and adding the rest purified water to the mixed solution to a constant volume to obtain an oral liquid;

Example 4

In a 10 ten thousand grade clean area, tablets for relieving depression are prepared, and the method comprises the following steps:

s1: inspecting and screening qualified raw materials, and weighing the following raw materials by mass: 100kg of casein hydrolysate peptide, 10kg of melissa officinalis extract, 10kg of German chamomile extract, 10kg of valerian root extract, 10kg of saffron extract, 100kg of blueberry extract, 100kg of tremella extract, 100kg of ginseng extract, 10000kg of xylitol, 25000kg of isomalt, 500kg of magnesium stearate, 200kg of silicon dioxide and 10kg of glucosyl stevioside;

s2: mixing casein hydrolysate peptide, Melissa officinalis extract, German chamomile extract, valerian root extract, saffron extract, blueberry extract, tremella extract and ginseng extract to obtain a mixture;

s3: adding xylitol, isomalt, magnesium stearate, silicon dioxide, glucosyl stevioside and magnesium stearate into the mixture in sequence, and mixing to obtain a mixture;

s4: the mixture obtained in step S3 was subjected to impurity removal by a magnet, and then tabletted (8 g/tablet), bottled, over-packed, and inspected and stored.

Example 5

s1: inspecting and screening qualified raw materials, and weighing the following raw materials by mass: 8000kg of casein hydrolysate peptide, 300kg of melissa officinalis extract, 450kg of German chamomile extract, 800kg of valerian root extract, 300kg of saffron extract, 3200kg of blueberry extract, 4001kg of tremella extract, 2100kg of ginseng extract, 19000kg of xylitol, 35000kg of isomalt, 1200kg of magnesium stearate, 620kg of silicon dioxide and 100kg of glucosyl stevioside;

Example 6

s1: inspecting and screening qualified raw materials, and weighing the following raw materials by mass: 15000kg of casein hydrolysate peptide, 1000kg of melissa officinalis extract, 1000kg of German chamomile extract, 1000kg of valerian root extract, 1000kg of saffron extract, 5000kg of blueberry extract, 5000kg of tremella extract, 5000kg of ginseng extract, 35000kg of xylitol, 50000kg of isomalt, 1500kg of magnesium stearate, 800kg of silicon dioxide and 200kg of glucosyl stevioside;

Example 7

The method for preparing the jelly for relieving depression in a 10 ten thousand grade clean area comprises the following steps:

s1: inspecting and screening qualified raw materials, and weighing the following raw materials by mass: 100kg of casein hydrolysate peptide, 10kg of melissa officinalis extract, 10kg of German chamomile extract, 10kg of valerian root extract, 10kg of saffron extract, 100kg of blueberry extract, 100kg of tremella extract, 100kg of ginseng extract, 10kg of potassium sorbate, 65000kg of purified water, 3000kg of erythritol, 10kg of citric acid monohydrate, 10kg of sodium citrate, 1kg of sucralose, 10kg of glucosyl stevioside and 500kg of jelly powder;

s2: premixing casein hydrolysate peptide, Melissa officinalis extract, German chamomile extract, valerian root extract, saffron extract, blueberry extract, tremella extract, ginseng extract, citric acid monohydrate, sodium citrate, sucralose and glucose-based stevioside, adding part of purified water, and stirring to obtain a mixed solution 18;

s3: mixing the jelly powder, erythritol, partially purified water and potassium sorbate, heating for dissolving, and adding the mixture 18 to obtain a mixture 19;

s4: adding the rest purified water into the mixed solution 19 to a constant volume to obtain a jelly stock solution;

s5: encapsulating the stock solution (40 + -5 deg.C, 10 g/piece), sterilizing (105 deg.C, 30min), cooling to below 60 deg.C, inspecting under lamp, packaging, inspecting, and warehousing.

Example 8

s1: inspecting and screening qualified raw materials, and weighing the following raw materials by mass: 8000kg of casein hydrolysate peptide, 300kg of melissa officinalis extract, 450kg of German chamomile extract, 800kg of valerian root extract, 300kg of saffron extract, 3200kg of blueberry extract, 4001kg of tremella extract, 2100kg of ginseng extract, 40kg of potassium sorbate, 81000kg of purified water, 7240kg of erythritol, 150kg of citric acid monohydrate, 157kg of sodium citrate, 3kg of sucralose, 140kg of glucosyl stevioside and 1000kg of jelly powder;

s2: premixing casein hydrolysate peptide, balm extract, German chamomile extract, valerian root extract, saffron extract, blueberry extract, tremella extract, ginseng extract, citric acid monohydrate, sodium citrate, sucralose and glucose-based stevioside, adding part of purified water, and stirring to obtain a mixed solution 20;

s3: mixing the jelly powder, erythritol, partially purified water and potassium sorbate, heating for dissolving, and adding the mixture 20 to obtain a mixture 21;

s4: adding the rest purified water into the mixed solution 21 to a constant volume to obtain a jelly stock solution;

Example 9

s1: inspecting and screening qualified raw materials, and weighing the following raw materials by mass: 15000kg of casein hydrolysate peptide, 1000kg of melissa officinalis extract, 1000kg of German chamomile extract, 1000kg of valerian root extract, 1000kg of saffron extract, 5000kg of blueberry extract, 5000kg of tremella extract, 5000kg of ginseng extract, 50kg of potassium sorbate, 95000kg of purified water, 10000kg of erythritol, 300kg of citric acid monohydrate, 300kg of sodium citrate, 5kg of sucralose, 200kg of glucosyl stevioside and 2000kg of jelly powder;

s2: premixing casein hydrolysate peptide, Melissa officinalis extract, German chamomile extract, valerian root extract, saffron extract, blueberry extract, tremella extract, ginseng extract, citric acid monohydrate, sodium citrate, sucralose and glucose-based stevioside, adding part of purified water, and stirring to obtain a mixed solution 22;

s3: mixing the jelly powder, erythritol, partially purified water and potassium sorbate, heating for dissolving, and adding the mixture 22 to obtain a mixture 23;

s4: adding the rest purified water into the mixed solution 23 to a constant volume to obtain a jelly stock solution;

Example 10

In a 10 ten thousand grade clean area, the preparation of the powder for relieving depression comprises the following steps:

s1: inspecting and screening qualified raw materials, and weighing the following raw materials by mass: 100kg of casein hydrolysate peptide, 10kg of melissa officinalis extract, 10kg of German chamomile extract, 10kg of valerian root extract, 10kg of saffron extract, 100kg of blueberry extract, 100kg of tremella extract, 100kg of ginseng extract, 10000kg of xylitol, 15000kg of polydextrose, 200kg of silicon dioxide, 0.1kg of sucralose, 10kg of citric acid monohydrate, 10kg of sodium citrate and 10kg of glucosyl stevioside;

s2: mixing casein hydrolysate peptide, Melissa officinalis extract, German chamomile extract, valerian root extract, saffron extract, blueberry extract, tremella extract and ginseng extract, sieving and screening to obtain undersize mixture 1;

s3: mixing xylitol, polydextrose, silicon dioxide, sucralose, citric acid monohydrate, sodium citrate and glucosyl stevioside, and sieving to obtain an undersize mixture 2;

s4: and mixing the undersize mixture 1 and the undersize mixture 2, bagging, externally packaging, inspecting and warehousing.

Example 11

s1: inspecting and screening qualified raw materials, and weighing the following raw materials by mass: 8000kg of casein hydrolysate peptide, 300kg of melissa officinalis extract, 450kg of German chamomile extract, 800kg of valerian root extract, 300kg of saffron extract, 3200kg of blueberry extract, 4001kg of tremella extract, 2100kg of ginseng extract, 23000kg of xylitol, 34000kg of polydextrose, 650kg of silicon dioxide, 2kg of sucralose, 230kg of citric acid monohydrate, 320kg of sodium citrate and 120kg of glucosyl stevioside;

s2: mixing casein hydrolysate peptide, Melissa officinalis extract, German chamomile extract, valerian root extract, saffron extract, blueberry extract, tremella extract and ginseng extract, sieving and screening to obtain undersize mixture 3;

s3: mixing xylitol, polydextrose, silicon dioxide, sucralose, citric acid monohydrate, sodium citrate and glucosyl stevioside, and sieving to obtain an undersize mixture 4;

s4: and mixing the undersize mixture 3 and the undersize mixture 4, bagging, externally packaging, inspecting and warehousing.

Example 12

s1: inspecting and screening qualified raw materials, and weighing the following raw materials by mass: 15000kg of casein hydrolysate peptide, 1000kg of melissa officinalis extract, 1000kg of German chamomile extract, 1000kg of valerian root extract, 1000kg of saffron extract, 5000kg of blueberry extract, 5000kg of tremella extract, 5000kg of ginseng extract, 35000kg of xylitol, 60000kg of polydextrose, 800kg of silicon dioxide, 10kg of sucralose, 500kg of citric acid monohydrate, 500kg of sodium citrate and 200kg of glucosyl stevioside;

s2: mixing casein hydrolysate peptide, Melissa officinalis extract, German chamomile extract, valerian root extract, saffron extract, blueberry extract, tremella extract and ginseng extract, sieving and screening to obtain undersize mixture 5;

s3: mixing xylitol, polydextrose, silicon dioxide, sucralose, citric acid monohydrate, sodium citrate and glucosyl stevioside, and sieving to obtain an undersize mixture 6;

s4: and mixing the undersize mixture 5 and the undersize mixture 6, bagging, externally packaging, inspecting and warehousing.

Experimental example 1

The tablets with depression relieving effect prepared in example 5 were subjected to animal experiments to verify the effects thereof, as follows:

modeling a depression model: establishing a chronic unpredictable stress (CUMS) depression model. During the experiment, mice were housed individually and randomly received 1 stressor per day. Mild stressors include the following: the cage body is inclined at 45 degrees for 24h, the cage body is used for swimming with ice water at 0 ℃ for 5min, no food is taken for 24h, no water is taken for 24h, the cage body is used for wetting the pad for 24h, the tail is clamped for 1min, the cage body is restrained in a 50mL tube for 6h, and the cage body is used for night illumination (2 times per week). The 8 stimuli were randomized and each occurred on average 3 times. The stimulation of the same species was not continuous, so that the mice could not expect the occurrence of the corresponding stimulation. Blank control mice (n-10) were housed in groups under normal conditions.

Grouping and administration of mice: after 24 days of chronic stress, the mice were randomly assigned to 6 groups, namely, the high dose group (0.5g/kg) in example 5, the medium dose group (0.2g/kg) in example 5, the low dose group (0.1g/kg) in example 5, the fluoxetine group (0.005g/kg) (for treating depression), the placebo group (given an equal volume of saline), and the depression model group (given an equal volume of saline), respectively. The gavage was given 1 dose/day for 14 days.

Tail suspension experiment (TST): after the last administration for 1h, the tail part of each group of mice is fixedly hung on an iron stand by an adhesive tape 2cm away from the tail end and 15cm away from the table top, and the cumulative immobile time of the tail suspension of the mice within 4min is calculated after the application is carried out for 2min (the mice are passively hung and are determined to be in an immobile state when limb movement disappears).

Forced Swimming Test (FST): the mice are firstly trained to swim for 5min after being administered for 1h for the last time, and are placed in a glass jar with the water depth of 10cm and the diameter of 20cm after 1d, the water temperature is kept at 25 ℃, the pre-adaptation is carried out for 2min, and then the immobility time of the mice within 4min is recorded (the mice show passive floating, and the struggling behavior disappears for 1min and is determined as the immobility state).

The data statistical method comprises the following steps: SPSS19.0 statistical software is adopted for data analysis, and normal distribution of the multiple groups of single-factor comparison is firstly analyzed by using a single factor and then counted by using an LSD method. P <0.05 is statistically significant.

Table 1 shows the influence of each sample on the immobility time of the tail suspension of the mice, and compared with a depression model group, the immobility time of the tail suspension of the mice in the high, medium and low dose groups and the fluoxetine group in example 5 is obviously shortened, and the comparison difference between the groups has statistical significance (P is less than 0.05 or P is less than 0.01), so that the product in example 5 can obviously enhance the motility of the mice and relieve depression.

TABLE 1

Group of	n	Dosage (g/kg)	Dead time(s)
				Example 5 high dose group	10	0.5	47.3±4.5**
Dose groups of example 5	10	0.2	60.1±4.8**
				Example 5 Low dose group	10	0.1	77.9±6.6*
Fluoxetine group	10	0.005	43.0±3.5**
				Blank control group	10	Equal volume	44.7±3.3
Depression model group	10	Equal volume	120.4±6.3

Note: "+" indicates P <0.05 and "+" indicates P < 0.01.

Table 2 shows the effect of each sample on the immobility time of forced swimming of mice, and compared with the depression model group, the immobility time of forced swimming of mice in the high, medium and low dose groups and fluoxetine group in example 5 is obviously shortened, and the comparison difference between the groups has statistical significance (P is less than 0.05 or P is less than 0.01). The product of example 5 is shown to be capable of significantly enhancing the mobility of mice and relieving depression.

TABLE 2

Group of	n	Dosage (g/kg)	Dead time(s)
				Example 5 high dose group	10	0.5	46.9±3.9**
Dose groups of example 5	10	0.2	58.6±4.4**
				Example 5 Low dose group	10	0.1	73.5±5.2*
Fluoxetine group	10	0.005	45.3±3.1**
				Blank control group	10	Equal volume	48.6±5.0
Depression model group	10	Equal volume	111.8±5.9

Note: "+" indicates P <0.05 and "+" indicates P < 0.01.

Finally, it should be noted that: the above description is only a preferred embodiment of the present invention, and is not intended to limit the scope of the present invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. The food composition for relieving depression is characterized by comprising the following components in parts by weight: 0.1-15 parts of casein hydrolysate peptide, 0.01-1 part of melissa officinalis extract, 0.01-1 part of yellow chrysanthemum extract, 0.01-1 part of valerian root extract, 0.01-1 part of saffron extract, 0.1-5 parts of blueberry extract, 0.1-5 parts of tremella extract and 0.1-5 parts of ginseng extract.

2. The food composition for relieving depression according to claim 1, comprising the following components in parts by weight: 8 parts of casein hydrolysate peptide, 0.34 part of melissa officinalis extract, 0.45 part of yellow chrysanthemum extract, 0.57 part of valerian root extract, 0.61 part of saffron extract, 3.9 parts of blueberry extract, 2.8 parts of tremella extract and 1.5 parts of ginseng extract.

3. The food composition for relieving depression according to claim 1, further comprising the following components in parts by mass: 65-95 parts of purified water, 3-10 parts of erythritol, 0.01-0.3 part of citric acid monohydrate, 0.01-0.3 part of sodium citrate, 0.01-0.3 part of DL-malic acid, 0.01-0.05 part of potassium sorbate, 0.001-0.005 part of sucralose and 0.01-0.2 part of edible spice.

4. The food composition for relieving depression according to claim 1, further comprising the following components in parts by mass: 10-35 parts of xylitol, 25-50 parts of isomalt, 0.5-1.5 parts of magnesium stearate, 0.2-0.8 part of silicon dioxide and 0.01-0.2 part of edible flavor.

5. The food composition for relieving depression according to claim 1, further comprising the following components in parts by mass: 65-95 parts of purified water, 0.5-2 parts of jelly powder, 3-10 parts of erythritol, 0.01-0.3 part of citric acid monohydrate, 0.01-0.3 part of sodium citrate, 0.01-0.05 part of potassium sorbate, 0.001-0.005 part of sucralose and 0.01-0.2 part of edible spice.

6. The food composition for relieving depression according to claim 1, further comprising the following components in parts by mass: 10-35 parts of xylitol, 15-60 parts of polydextrose, 0.2-0.8 part of silicon dioxide, 0.001-0.01 part of sucralose, 0.01-0.5 part of citric acid monohydrate, 0.01-0.5 part of sodium citrate and 0.01-0.2 part of edible spice.

7. A method of preparing the food composition for alleviating depression according to claim 3, comprising the steps of:

8. A method for preparing the food composition for relieving depression according to claim 4, comprising the steps of:

and removing impurities from the mixture 2 and tabletting.

9. A method of preparing the food composition for alleviating depression according to claim 5, comprising the steps of:

and mixing the mixture 3 and the mixed solution 3, and fixing the volume.

10. A method of preparing the food composition for alleviating depression according to claim 6, comprising the steps of: sieving casein hydrolysate peptide, Melissa officinalis extract, yellow chrysanthemum extract, rhizoma et radix Valerianae extract, stigma croci Sativi extract, fructus Myrtilli extract, Tremella extract, potassium sorbate and Ginseng radix extract respectively, and premixing to obtain mixture 4;

mixing the mixture 4 and the mixture 5.